The future of serology in cancer care looks promising with ongoing research and advancements in technology. Emerging techniques such as liquid biopsy are enhancing the ability to detect cancer-related biomarkers with greater precision. Additionally, the integration of artificial intelligence and machine learning in analyzing serological data is expected to improve the accuracy and predictive value of these tests.
